Articles

The COVID-19 pandemic may have temporarily overshadowed the opioid crisis in the United States, but deaths related to opioid overdose have risen to an all-time high in the past year. Read More ›

Treatment with tebentafusp (IMCgp100), a novel bispecific T-cell receptor (TCR) fusion protein, extended survival in patients with metastatic uveal melanoma, according to the results from a recent phase 3 trial. Read More ›

Hot flashes, fatigue, back and joint pain, and anxiety are some of the symptoms and concerns frequently reported by early-stage breast cancer survivors, according to results from a study of 98 women with low-risk stage I/II estrogen/progesterone-positive, HER2/neu-negative cancers. Read More ›

• Daily Aspirin Does Not Lower CRC Risk When Started After Age 70
• Adjuvant Nivolumab Therapy Prolongs Disease-Free Survival in Patients with Esophageal Cancer
• New Data Reveal Mismatched Need and Supply of Oncology Physicians and Pharmacists

Read More ›

Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease. Read More ›

Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving. In the past 10 years alone, the number of drugs approved by the FDA for non–small-cell lung cancer (NSCLC) has exceeded the previous 10 decades combined. Read More ›

Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. Although the exact prevalence of CCA is unknown, CCA is a rare cancer; approximately 8000 new cases of CCA are diagnosed annually in the United States. Read More ›

Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations. Read More ›

A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy. Read More ›

Subgroup analysis of CodeBreaK 100 trial results found that sotorasib achieved a response in pretreated patients with KRAS^G12C-mutated NSCLC subtypes. Read More ›